OPTH — Optimi Health Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2027329 ·
Last close
$4.85
Market Cap
$27.77M
52W High
$6.40
52W Low
$4.00
ADV30
51,517
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 140,200 | 66,623 | -2,134,695 | -2,404,430 | 25,861,164 | 13,073,333 | 8,223,125 |
| Mar 2026 | 99,500 | 89,464 | -1,356,912 | -1,591,871 | 13,509,676 | 106,711 | 9,971,230 |
| Dec 2025 | 0 | 0 | -1,280,597 | -1,553,975 | 14,236,203 | 491,750 | 9,219,190 |
| Sep 2025 | -64,029 | -464,233 | -1,667,227 | -1,349,367 | 15,212,645 | 1,145,065 | 8,641,984 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,205,981
Investing CF
$-88,411
Financing CF
$3,345,389
CapEx
$-88,411
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-08-20
Balance + Analyst (yfinance extras)
Retained Earnings
$-29,853,753
Inventory
$300,352
Receivables
$44,128
ST Investments
—
EBIT TTM
$-4,574,734
Pretax Income TTM
$-5,402,531
Interest Exp TTM
$827,797
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$175,671
EBITDA
$-4,207,583
Free Cash Flow
$-1,725,642
Enterprise Value
$17,379,542
Total Cash
$13,073,333
Total Debt
$5,144,542
Shares Out
5,725,867
Trailing EPS
$-1.46
Book Value
$2.23
ROE
-54.4%
ROA
-16.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 426,301 | -4,612,279 | -3,712,031 | 15,212,645 | 8,641,984 | 6,570,661 | -2,627,901 |
| Sep 2024 | 389,850 | -5,609,185 | -6,035,859 | 14,551,035 | 4,975,323 | 9,575,712 | -4,281,693 |
| Sep 2023 | 181,087 | -5,272,295 | -5,194,548 | 16,491,729 | 3,280,836 | 13,210,893 | -3,601,537 |
| Sep 2022 | 80,717 | -7,389,778 | -7,350,828 | 16,817,771 | 797,665 | 16,020,106 | -4,579,541 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDNAF | Medicenna Therapeutics Corp. | $27.87M | $0.30 | — |
| KYNB | KYNTRA BIO, INC. | $27.94M | $6.90 | — |
| ABVC | ABVC BIOPHARMA, INC. | $27.99M | $1.05 | — |
| IGC | IGC Pharma, Inc. | $28.33M | $0.27 | — |
| CLCS | Cell Source, Inc. | $28.50M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial
2026-09-23 15:58 · Yahoo
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
2026-09-23 13:00 · Yahoo
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
2026-09-22 13:00 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-09-21 15:01 · Yahoo
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
2026-09-19 00:30 · Yahoo
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
2026-09-10 12:45 · Yahoo
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:30 · Yahoo
Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances
2026-08-19 06:03 · Yahoo
Optimi Health Establishes Discretionary Equity Facility
2026-08-14 20:55 · Yahoo
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
2026-09-17 21:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.